Poor persistence with medication in patients with osteoporosis

A quarter of patients with osteoporosis are stopping bisphosphonate therapy at six months, a new Australian report shows.

The Australian Institute of Health and Welfare report on the use of antiresorptive agents for osteoporosis showed 60% of patients had an adequate supply of non-etidronate antiresorptives for compliance over 12 months.

The report, which looked at use of the drugs between 2003 and 2007, showed 10% of patients had only received one prescription of antiresorptives, primarily alendronate and risedronate, after starting treatment.

“There appears to be a clear need to monitor the use of antiresorptive therapy, particularly in the first six or seven months to ensure appropriate health benefits are obtained,” the report stated.